Results 21 to 30 of about 22,112 (155)
Immunohistochemical Expression of Programmed Death Ligand-1 in Tumour Milieu of Oral Cancer
Annals of Abbasi Shaheed Hospital and Karachi Medical & Dental College, 2020 Objectives: To determine the immunohistochemical expression of PD-L1 in oral squamous cell carcinoma and to correlate it with clinicopathological parameters.
Moomal Aslam Khan +3 more
doaj +1 more source
Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors [PDF]
, 2016 PURPOSE: Subsets of pituitary tumors exhibit an aggressive clinical courses and recur despite surgery, radiation, and chemotherapy. Because modulation of the immune response through inhibition of T-cell checkpoints has led to durable clinical responses ...
Agar, Nathalie Y. R. +13 more
core +3 more sources
OncoTargets and Therapy, 2014 The aim of this study was to examine whether short hairpin RNA (shRNA) expressing lentiviral particles targeting B7-H1 infection could result in B7-H1 knockdown on dendritic cells (DCs) and to investigate whether B7-H1 silencing could augment the immune function of DCs and further elicit a more potent anti-tumor immune effect against bladder cancer ...
Wang, Shuo +7 more
openaire +4 more sources
Immunological backbone of uveal melanoma: is there a rationale for immunotherapy? [PDF]
, 2019 No standard treatment has been established for metastatic uveal melanoma (mUM). Immunotherapy is commonly used for this disease even though UM has not been included in phase III clinical trials with checkpoint inhibitors.
Alessandra Cassano +24 more
core +1 more source
CTLA-4 and PD-1 ligand gene expression in epithelial thyroid cancers [PDF]
, 2018 The dysregulation of PD-1 ligands (PD-L1 and PD-L2) and CTLA-4 ligands (CD80 and CD86) represents a tumor strategy to escape the immune surveillance. Here, the expression of PD-L1, PD-L2, CD80 and CD86 was evaluated at mRNA level in 94 patients affected ...
Antonelli, Alessandro +15 more
core +3 more sources
Immunocompetent murine models for the study of glioblastoma immunotherapy. [PDF]
, 2014 Glioblastoma remains a lethal diagnosis with a 5-year survival rate of less than 10%. (NEJM 352:987-96, 2005) Although immunotherapy-based approaches are capable of inducing detectable immune responses against tumor-specific antigens, improvements in ...
Bloch, Orin +9 more
core +2 more sources
B7 costimulation and intracellular indoleamine-2,3-dioxygenase (IDO) expression in peripheral blood of healthy pregnant and non-pregnant women. [PDF]
, 2014 BACKGROUND: B7 costimulatory molecules are expressed on antigen presenting cells (APCs) and are important regulators of T cell activation. We investigated the role of the B7 family of costimulatory molecules in the development of the systemic maternal ...
A Hutloff +30 more
core +2 more sources
Biomarker Research, 2020 Background On-target off-tumor toxicity impedes the clinical application of chimeric antigen receptor-modified T cells (CAR-T cells) in the treatment of solid tumors.
Qibin Liao +5 more
doaj +1 more source
Pattern of differential expression of costimulatory molecules in myeloma cell line MM1.R
Revista Médica del Hospital General de México, 2018 T cells constantly recognise and eliminate circulating tumour cells. They require two signals in order to be activated: antigen presentation via TCR, and costimulatory interaction with different surface molecules of the B7 family, which may either ...
A. De la Cruz-Rosas +4 more
doaj +1 more source
HDAC inhibition potentiates immunotherapy in triple negative breast cancer. [PDF]
, 2017 Triple-negative breast cancer (TNBC) represents a more aggressive and difficult subtype of breast cancer where responses to chemotherapy occur, but toxicity is significant and resistance often follows. Immunotherapy has shown promising results in various
Ali, Niwa +8 more
core +1 more source